PT UBC Medical Indonesia Tbk
IIDX:LABS136.00
IDR
0.00
(0.00%)
ISIN
ID1000205305
Return %
Stock
S&P 500
1Y
-3.55
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Franciscus Xaverius Raintjung
- Full Time Employees
- 54
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Kawasan Industri Pulogadung Jakarta JK Indonesia 13930
- IPO Date
- Jul 10, 2024
- Website
- ubcindonesia.com
- Similar Companies
- Business
- PT UBC Medical Indonesia Tbk (LABS.JK) distributes medical devices and diagnostics in Indonesia. The company operates through two segments, Medical Disposables and Consumables, and Diagnostics and Equipment; it offers next generation molecular systems such as NeoMoDX Molecular System and QIAstat-DX Analyzer, retina AI solutions including Airdoc, infectious disease tests like Revvity SARS-COV-2 RT PCR and Geneproof SARS-COV-2 PCR KIT, HPV DNA tests via Care HPV System and Hybrid Capture 2, real-time PCR and TB management products such as Quantiferon TB Gold Plus, Ina TB and Genoscholar, and newborn screening kits including GSP Neonatal Kit, Delfia Neonatal Kit, Neonatal Sampling Paper and Victor2 D; it also provides immunoassay, urinalysis and laboratory support equipment through partnerships with global firms like QIAGEN, PerkinElmer, NIPRO and Global Biological Corp. Founded in 2014 and headquartered in Jakarta Timur, the company targets government entities, laboratories and healthcare providers across Indonesia as a subsidiary of PT Optel Investama Mulia with PT Esora Medika Indonesia as its manufacturing subsidiary for lab equipment. In July 2024, PT UBC Medical Indonesia Tbk completed its initial public offering on the Indonesia Stock Exchange, issuing 700 million shares at IDR 102 each to raise funds for expansion amid 8% sales growth to IDR 147.64 billion.